Intermittent Theta-Burst Stimulation to Target Irritability in Adults With ASD

Autism Spectrum Disorder Clinical Trial

Official title:

Intermittent Theta-Burst Stimulation to Target Irritability in Adults With ASD

Clinical Trial Details — Status: Withdrawn

Administrative data

• NCT number: NCT04316338
• Other study ID #: IRB-41458
• Status: Withdrawn
• Phase: N/A
• Start date: May 1, 2022
• Est. completion date: May 1, 2025

Study information

• Verified date: November 2023
• Source: Stanford University
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This study aims to demonstrate the feasibility, tolerability, safety and preliminary efficacy of 6 weeks of fMRI-guided iTBS delivered to personalized regions of the prefrontal cortex (PFC) in adults with ASD in reducing irritability in adults with ASD.

Recruitment information / eligibility

• Status: Withdrawn
• Enrollment: 0
• Est. completion date: May 1, 2025
• Est. primary completion date: May 1, 2024
• Accepts healthy volunteers: No
• Gender: All
• Age group: 22 Years to 55 Years

Eligibility

Inclusion Criteria:

1. Diagnosis of ASD or Asperger's based on DSM-5 criteria as confirmed by a qualified clinician (including Dr. Fung), and if necessary the administration of Autism Diagnostic Interview-Revised (ADI-R) and/or Autism Diagnostic Observation Schedule-Generic (ADOS-G)

2. Age 22 to 55.

3. Adults who are physically healthy.

4. No significant current psychosocial stressors per history.

5. Full scale IQ > 50.

6. ABC-I score of 18 or greater.

7. if the participant is taking medication, they must be stable on this medication regiment for at least 4 weeks prior to baseline and agree to stay on these medications for the duration of the trial Exclusion Criteria: (f) Pre-term birth (<34 weeks' gestation) (g) Low birth weight (<2000 g). (h) DSM-5 diagnosis of other severe psychiatric disorder such as bipolar disorder or schizophrenia. (i) Current use of benzodiazepines. (j) Use of other medications that modulate the GABA(A) receptor within 4 weeks of scanning (8 weeks for fluoxetine). (k) History of alcoholism or substance abuse. (l) Active medical problems such as unstable seizures, congenital heart disease, endocrine disorders. (m) Significant sensory impairments such as blindness or deafness. (n) Contraindication for MRI. (o) Pregnancy. (p) evidence of genetic syndrome.

Related Conditions & MeSH terms

• Autism Spectrum Disorder

Intervention

Device:
• Intermittent theta-burst stimulation (iTBS)
Non-invasive brain stimulation technique

Locations

Country	Name	City	State
n/a

Sponsors (1)

Lead Sponsor	Collaborator
Stanford University

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Aberrant Behavior Checklist-irritability subscale (ABC-I)	A parent/caregiver/clinician completed checklist (58-item) with an irritability subscale (15-item). Each item has a maximum score of 3, meaning that the irritability subscale has a maximum score of 45 and minimum score of 0. Higher scores indicate higher levels of irritability.	Change across time: Baseline minus immediately after final treatment
Secondary	Irritability Questionnaire	A 21-item self-report measure of irritability. Each item is rated on how often (Never=0 to Most of the time=4) and the intensity (Not at all=0, Very much so=4) at which they occur.	Baseline, every week of treatment (1-6), immediately after treatment, one month after treatment.
Secondary	Self-injury questionnaire (SIQ)	Self-report measure of self-injury, maximum 60 questions but participants only answer relevant questions. Five types of self-injurious behaviors are checked: scratching, bruising, cutting, burning, and biting oneself. It will assess the taxonomic specifications of self-injurious behavior (SIB- (e.g., type, frequency, duration)), but also the affective antecedents and consequences as well as the functions of each type of SIB.	Baseline, immediately after treatment, one month after treatment.
Secondary	THE MODIFIED OVERT AGGRESSION SCALE (MOAS)	Clinician rated scale of aggression. 4 items rated from 0-4. Maximum score is 16 with higher scores indicating higher levels of aggression, used to evaluate and document the "frequency and severity" of aggressive episodes.	Baseline, immediately after treatment, one month after treatment.
Secondary	Difficulties in Emotion Regulation Scale	Self-report measure of emotion regulation, evaluating individuals' levels of difficulties in regulating emotions. 36-item questionnaires. Each question rated from 1-5. Maximum score is 180 with higher scores indicating greater difficulty in emotion regulation. The instrument presents 36 items on a 5-point Likert scale of frequency (from 1 = almost never, to 5 = almost always).	Baseline, immediately after treatment, one month after treatment.
Secondary	The Adult Autism Quotient (AQ)	50-item self-report measure of autistic traits. Each of 50 statements are rated from 'definitely disagree' to 'definitely agree'.	Baseline, immediately after treatment, one month after treatment.
Secondary	Repetitive Behavior Scale-Revised (RBS-R)	43-item clinician rated scale measuring repetitive behaviors associated with ASD. Each item is rated from 0 (behavior does not occur) to 3 (behavior is a severe problem)	Baseline, immediately after treatment, one month after treatment.
Secondary	Montgomery-Åsberg Depression Rating Scale (MADRS)	10-item clinician rated measure of depressive symptoms. Each item is rated on a scale of 1-6.	Baseline, immediately after treatment, one month after treatment.
Secondary	Functional connectivity between areas involved in negative emotion regulation	Functional magnetic resonance imaging (fMRI) will be used to measure functional connectivity between areas involved in emotion regulation, previously shown to be involved in irritability. Areas of interest include: ventromedial prefrontal cortex, the amygdala, dorsolateral prefrontal cortex, the striatum.	Baseline, immediately after treatment, one month after treatment.
Secondary	EEG recordings	Electroencephalography (EEG) will be used to measure brain activity and connectivity before and after treatment. Resting-state EEG (5 minutes) with eyes open and TMS-evoked potential recordings will be taken before and after treatment. We are particularly interested in measuring gamma band activity (>30Hz) in participants while at rest.	Baseline, immediately after treatment, one month after treatment.
Secondary	Magnetic resonance spectroscopy (MRS)	MRS will be used to measure GABA levels in two brain areas of interest (ventromedial prefrontal cortex and amygdala) before and after treatment.	Baseline, immediately after treatment, one month after treatment.
Secondary	Aberrant Behavior Checklist-irritability subscale (ABC-I)	A parent/caregiver/clinician completed checklist (58-item) with an irritability subscale (15-item). Each item has a maximum score of 3, meaning that the irritability subscale has a maximum score of 45 and minimum score of 0. Higher scores indicate higher levels of irritability.	Change across time: Baseline minus one month after treatment